Clinical Trial

The Application of Biomarkers in the Care of Patients With Atrial Fibrillation

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Administrative withdrawal: This study was determined to be a continuation of \[NCT05718336\]. To avoid duplicate reporting and ensure consistent publication, this record is being consolidated into the prior study. No enrollment has occurred.
Summary
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
Protocol Amendment History 2 changes
critical Trial status changed: Active, Not Recruiting → Withdrawn 2026-05-08
notable Enrollment reduced: 266 -> 0 participants 2026-05-08
Trial Details
NCT Number NCT07565337
Lead Sponsor National Taiwan University Hospital
Conditions Atrial Fibrillation, Biomarker
Start Date 2026-01-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07